clinicalof osimertinib responder small cell lung cancer patients with egfr t790m临床反应在非小细胞肺癌患者EGFR T790M突变中.pdf

Clinicalcharacteristicsofosimertinib

responderinnon-smallcelllungcancer

patientswithEGFR-T790Mmutation

1123

T.Yamada,A.Yoshimura,T.Takeda,S.Shiotsu,

4511

O.Hiranuma,Y.Chihara,J.Uchino,K.Takayama

12

KyotoPrefecturalUniversityofMedicine,Kyoto/Japan,Japanese

3

RedCrossKyotoDainiHospital,Kyoto/Japan,JapaneseRedCross

4

KyotoDaiichiHospital,Kyoto/Japan,Otsucityhospital,Otsu/Japan,

5Uji-TokushukaiMedicalCenter,Kyoto/Japan

PresenterName,Institution,Country

DISCLOSURES

Idonothaveanyrelevantfinancialrelationshipstodisclose.

Osimertinibisamutant-selectiveEGFRinhibitorthatiseffectiveagainstnon-smallcelllungcancer

(NSCLC)inpatientswiththeEGFR-T790Mmutation,whoareresistanttoEGFR-tyrosinekinase

inhibitors(EGFR-TKIs).However,thefactorsaffectingresponsetoosimertinibtreatmentareunknown.

Inthisretrospectivestudy,27NSCLCpatientswiththeEGFR-T790Mmutationwereenrolledatfive

institutionsinJapan.Amongseveralparameterstested,theprogression-freesurvival(PFS)associated

withtheinitialEGFR-TKIswaspositivelycorrelatedwiththePFSafterosimertinibtreatment(p=

0.021).ThemedianPFSfollowingosimertinibtreatmentandtheoverallsurvival(OS)werelongerin

patientswhorespondedtoosimertinibthaninthosewhodidnot(17.7monthsversus3.5months,p=

0.009and24.2monthsversus13.5months,p=0.021,respectively).Amultivari